Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Post by MonkVestoron Feb 15, 2020 3:06am

205 Views

Post# 30694806

Update on Stockwatch

Kalytera Therapeutics 7,983,000 shares for debt

2020-02-14 18:07 ET - Shares for Debt

The TSX Venture Exchange has accepted for filing the company's proposal to issue 7,983,000 shares at a deemed price of five cents per share to settle outstanding debt for $399,150.

Number of creditors: one creditor

Insider/pro group participation: none

The company shall issue a news release when the shares are issued and the debt extinguished.

Bullboard Posts

How one company is disrupting PoC testing